MET and neoplasm: Cabozantinib is a selective angiogenic inhibitor with a high affinity to VEGFR-2 (IC50 = 0.035 nM), c-Met (IC50 = 1.3 nM), c-Kit (IC50 = 4.6 nM), Tie-2 (IC50 = 14.3 nM), Flt-3 (IC50 = 11.3 nM), and Ret (IC50 = 5.2 nM), which is a bismethoxyquinoline analog (Table 1).429,430 Because of the ability to inhibit autophosphorylation of VEGFR-2 and c-Met, cabozantinib exhibited decent anti-tumor, anti-metastatic, and anti-angiogenic activities in preclinical models.